What's in Endo USA, Inc.'s pipeline?

Endo USA, Inc. has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Endo USA, Inc.'s portfolio?

Top competitors by shared drug class: Assiut University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/endo-usa-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Endo USA, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endo USA, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Aplisol	TUBERCULIN	marketed	Skin Test Antigen [EPC]		Immunology

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assiut University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Endo USA, Inc.:

Cite this brief

Drug Landscape (2026). Endo USA, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/endo-usa-inc. Accessed 2026-05-16.